SGX:H02Pharmaceuticals
Haw Par (SGX:H02) Cools After Half Year Earnings As Valuation Questions Grow
Haw Par (SGX:H02) reported its half year 2026 results on 14 August, with sales of S$115.93 million and net income of S$107.87 million, both lower than the prior year period.
See our latest analysis for Haw Par.
Haw Par's recent half year result appears to have cooled momentum, with the share price at S$15.50 and a 30 day share price return of 7.9% lower, even as the 3 year total shareholder return of 92.48% remains strong.
If Haw Par's latest move has you reassessing your watchlist, this...